1. Advances in experimental systems to study hepatitis C virus in vitro and in vivo.

    Virology 479-480:221 (2015) PMID 25847726

    Hepatitis C virus (HCV) represents a global health concern affecting over 185 million people worldwide. Chronic HCV infection causes liver fibrosis and cirrhosis and is the leading indication for liver transplantation. Recent advances in the field of direct-acting antiviral drugs (DAAs) promise ...
  2. Hepatitis C Virus RNA Functionally Sequesters miR-122.

    Cell 160(6):1099 (2015) PMID 25768906

    Hepatitis C virus (HCV) uniquely requires the liver-specific microRNA-122 for replication, yet global effects on endogenous miRNA targets during infection are unexplored. Here, high-throughput sequencing and crosslinking immunoprecipitation (HITS-CLIP) experiments of human Argonaute (AGO) during...
  3. Hepatitis C Virus RNA Functionally Sequesters miR-122.

    Cell 160(6):1099 (2015) PMID 25768906 PMCID PMC4386883

    Hepatitis C virus (HCV) uniquely requires the liver-specific microRNA-122 for replication, yet global effects on endogenous miRNA targets during infection are unexplored. Here, high-throughput sequencing and crosslinking immunoprecipitation (HITS-CLIP) experiments of human Argonaute (AGO) during...
  4. Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agents.

    Hepatology 60(5):1508 (2014) PMID 24797654 PMCID PMC4211977

    Hepatitis C virus (HCV)-induced endstage liver disease is currently a major indication for liver transplantation. After transplantation the donor liver inevitably becomes infected with the circulating virus. Monoclonal antibodies (mAbs) against the HCV coreceptor scavenger receptor class B type ...
  5. Role of hypervariable region 1 for the interplay of hepatitis C virus with entry factors and lipoproteins.

    Journal of Virology 88(21):12644 (2014) PMID 25142595 PMCID PMC4248924

    Hepatitis C virus (HCV) particles associate with lipoproteins and infect cells by using at least four cell entry factors. These factors include scavenger receptor class B type I (SR-BI), CD81, claudin 1 (CLDN1), and occludin (OCLN). Little is known about specific functions of individual host fac...
  6. Role of hypervariable region 1 for the interplay of hepatitis C virus with entry factors and lipoproteins.

    Journal of Virology 88(21):12644 (2014) PMID 25142595

    Hepatitis C virus (HCV) particles associate with lipoproteins and infect cells by using at least four cell entry factors. These factors include scavenger receptor class B type I (SR-BI), CD81, claudin 1 (CLDN1), and occludin (OCLN). Little is known about specific functions of individual host fac...
  7. Role of hypervariable region 1 for the interplay of hepatitis C virus with entry factors and lipoproteins.

    Journal of Virology 88(21):12644 (2014) PMID 25142595 PMCID PMC4248924

    Hepatitis C virus (HCV) particles associate with lipoproteins and infect cells by using at least four cell entry factors. These factors include scavenger receptor class B type I (SR-BI), CD81, claudin 1 (CLDN1), and occludin (OCLN). Little is known about specific functions of individual host fac...
  8. Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agents.

    Hepatology 60(5):1508 (2014) PMID 24797654 PMCID PMC4211977

    Hepatitis C virus (HCV)-induced endstage liver disease is currently a major indication for liver transplantation. After transplantation the donor liver inevitably becomes infected with the circulating virus. Monoclonal antibodies (mAbs) against the HCV coreceptor scavenger receptor class B type ...
  9. Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agents.

    Hepatology 60(5):1508 (2014) PMID 24797654 PMCID PMC4211977

    Hepatitis C virus (HCV)-induced endstage liver disease is currently a major indication for liver transplantation. After transplantation the donor liver inevitably becomes infected with the circulating virus. Monoclonal antibodies (mAbs) against the HCV coreceptor scavenger receptor class B type ...
  10. Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agents.

    Hepatology 60(5):1508 (2014) PMID 24797654 PMCID PMC4211977

    Hepatitis C virus (HCV)-induced endstage liver disease is currently a major indication for liver transplantation. After transplantation the donor liver inevitably becomes infected with the circulating virus. Monoclonal antibodies (mAbs) against the HCV coreceptor scavenger receptor class B type ...
  11. Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agents.

    Hepatology 60(5):1508 (2014) PMID 24797654 PMCID PMC4211977

    Hepatitis C virus (HCV)-induced endstage liver disease is currently a major indication for liver transplantation. After transplantation the donor liver inevitably becomes infected with the circulating virus. Monoclonal antibodies (mAbs) against the HCV coreceptor scavenger receptor class B type ...
  12. Role of hypervariable region 1 for the interplay of hepatitis C virus with entry factors and lipoproteins.

    Journal of Virology 88(21):12644 (2014) PMID 25142595 PMCID PMC4248924

    Hepatitis C virus (HCV) particles associate with lipoproteins and infect cells by using at least four cell entry factors. These factors include scavenger receptor class B type I (SR-BI), CD81, claudin 1 (CLDN1), and occludin (OCLN). Little is known about specific functions of individual host fac...
  13. Completion of the entire hepatitis C virus life cycle in genetically humanized mice.

    Nature 501(7466):237 (2013) PMID 23903655 PMCID PMC3858853

    More than 130 million people worldwide chronically infected with hepatitis C virus (HCV) are at risk of developing severe liver disease. Antiviral treatments are only partially effective against HCV infection, and a vaccine is not available. Development of more efficient therapies has been hampe...
  14. Completion of the entire hepatitis C virus life cycle in genetically humanized mice.

    Nature 501(7466):237 (2013) PMID 23903655 PMCID PMC3858853

    More than 130 million people worldwide chronically infected with hepatitis C virus (HCV) are at risk of developing severe liver disease. Antiviral treatments are only partially effective against HCV infection, and a vaccine is not available. Development of more efficient therapies has been hampe...
  15. Different requirements for scavenger receptor class B type I in hepatitis C virus cell-free versus cell-to-cell transmission.

    Journal of Virology 87(15):8282 (2013) PMID 23698298 PMCID PMC3719822

    Hepatitis C virus (HCV) is believed to initially infect the liver through the basolateral side of hepatocytes, where it engages attachment factors and the coreceptors CD81 and scavenger receptor class B type I (SR-BI). Active transport toward the apical side brings the virus in close proximity o...
  16. Different requirements for scavenger receptor class B type I in hepatitis C virus cell-free versus cell-to-cell transmission.

    Journal of Virology 87(15):8282 (2013) PMID 23698298 PMCID PMC3719822

    Hepatitis C virus (HCV) is believed to initially infect the liver through the basolateral side of hepatocytes, where it engages attachment factors and the coreceptors CD81 and scavenger receptor class B type I (SR-BI). Active transport toward the apical side brings the virus in close proximity o...
  17. Ultrastructural analysis of hepatitis C virus particles.

    PNAS 110(23):9505 (2013) PMID 23690609 PMCID PMC3677472

    Hepatitis C virus (HCV) is a major cause of chronic liver disease, with an estimated 170 million people infected worldwide. Low yields, poor stability, and inefficient binding to conventional EM grids have posed significant challenges to the purification and structural analysis of HCV. In this r...
  18. Ultrastructural analysis of hepatitis C virus particles.

    PNAS 110(23):9505 (2013) PMID 23690609 PMCID PMC3677472

    Hepatitis C virus (HCV) is a major cause of chronic liver disease, with an estimated 170 million people infected worldwide. Low yields, poor stability, and inefficient binding to conventional EM grids have posed significant challenges to the purification and structural analysis of HCV. In this r...
  19. A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo.

    Hepatology 55(2):364 (2012) PMID 21953761 PMCID PMC3262867

    Endstage liver disease caused by chronic hepatitis C virus (HCV) infection is the leading indication for liver transplantation in the Western world. However, immediate reinfection of the grafted donor liver by circulating virus is inevitable and liver disease progresses much faster than the orig...
  20. A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo.

    Hepatology 55(2):364 (2012) PMID 21953761 PMCID PMC3262867

    Endstage liver disease caused by chronic hepatitis C virus (HCV) infection is the leading indication for liver transplantation in the Western world. However, immediate reinfection of the grafted donor liver by circulating virus is inevitable and liver disease progresses much faster than the orig...